Navigation Links
Palatin Technologies, Inc. Reports Second Quarter Fiscal Year 2011 Results
Date:2/15/2011

CRANBURY, N.J., Feb. 15, 2011 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE Amex: PTN) a biopharmaceutical company dedicated to the development of peptide mimetic and small molecule agonist compounds with a focus on melanocortin and natriuretic peptide receptor systems, today announced results for its second quarter ended December 31, 2010.  Palatin reported a net loss of $1.1 million, or $(0.09) per basic and diluted share, for the quarter ended December 31, 2010, compared to net income of $4.5 million, or $0.42 per basic and diluted share, for the same period in 2009.  

The net loss for the quarter ended December 31, 2010, compared to net income for the same period last fiscal year, was primarily attributable to a decrease in revenue recognized under Palatin's research collaboration and license and clinical trial collaboration agreements with AstraZeneca AB (AstraZeneca) as a result of the successful completion of the research collaboration portion of the agreements.

REVENUERevenues for the quarter ended December 31, 2010 were $1.0 million, consisting of $846,768 in grant revenue received under the Patient Protection and Affordable Care Act of 2010 and $195,408 in contract revenue pursuant to the collaboration agreement with AstraZeneca. For the quarter ended December 31, 2009, Palatin recognized $7.3 million of contract revenue under its collaboration agreement with AstraZeneca.

COSTS AND EXPENSESTotal operating expenses for the quarter ended December 31, 2010 were $2.9 million compared to $3.8 million for the comparable quarter of 2009.  The net decrease in operating expenses for the quarter was primarily due to Palatin's previously disclosed realignment of resources and reduction in staffing levels.

CASH POSITION / GOING CONCERNPalatin's cash, cash equivalents and investments were $3.7 million as of December 31, 2010, compar
'/>"/>

SOURCE Palatin Technologies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2011 Results; Teleconference and Webcast to be held on November 16, 2010
2. Palatin Technologies, Inc. to Report Fiscal Year 2011 First Quarter Results; Teleconference and Webcast to be Held on November 16, 2010
3. Palatin Announces Strategic Realignment of Operations
4. Palatin Technologies, Inc. to Raise $2.0 Million Dollars in Registered Direct Offering
5. Palatin Technologies, Inc. Reports Second Quarter Fiscal Year 2010 Results; Teleconference and Webcast to be held on February 16, 2010
6. Palatin Technologies, Inc. Issued U.S. Patent for Heart Failure Drug Candidate
7. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2010 Results; Teleconference and Webcast to be held on November 16, 2009
8. Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2009 Results; Teleconference and Webcast to be held on September 8, 2009
9. Palatin Technologies, Inc. to Report Fourth Quarter and Fiscal Year 2009 Results; Teleconference and Webcast to be held on September 8, 2009
10. Palatin Technologies to Present at the Rodman & Renshaw 11th Annual Global Investment Conference
11. Palatin Technologies, Inc. to Raise $3.1 Million in Registered Direct Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... York (PRWEB) July 25, 2014 According ... Research, "Biological Drugs Market - Global Industry Analysis, Size, ... global biological drugs market is estimated at USD 161,056.5 ... a CAGR of 10.1% from 2014 to 2020, to ... 2020. , The biological drugs market is witnessing a ...
(Date:7/25/2014)... The Conferee Networking committee is pleased ... Networking. These two-hour sessions provide a unique networking opportunity ... problems, discuss new techniques, or brainstorm new ideas in ... topic for consideration is August 31, 2014, and instructions ... Networking committee will review the topics, and status notifications ...
(Date:7/25/2014)... 25, 2014  Galmed Pharmaceuticals Ltd. (Nasdaq: ... the development and commercialization of a once-daily, oral therapy ... today announced financial results for the period ended June ... , Reported cash and cash equivalents totaling $37.4 ... December 31, 2013.  , Reported a net loss ...
(Date:7/25/2014)... At the request of the AMA, the Federal ... the public comment period (Docket No. FAA-2014-0396) for FAA’s ... by Congress as part of the FAA Modernization and ... new deadline for comments as September 23, 2014. , ... in the Federal Register on July 25, 2014, the ...
Breaking Biology Technology:Biological Drugs Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 2Biological Drugs Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 3Pittcon 2015 Announces Call for Topics for Conferee Networking Sessions 2Galmed Pharmaceuticals Reports First Half 2014 Financial Results 2Galmed Pharmaceuticals Reports First Half 2014 Financial Results 3Galmed Pharmaceuticals Reports First Half 2014 Financial Results 4Galmed Pharmaceuticals Reports First Half 2014 Financial Results 5Galmed Pharmaceuticals Reports First Half 2014 Financial Results 6FAA Grants Comment Extension at the Request of AMA 2
... during the first quarter of 2005 amid poor overall stock ... at the larger cap life science companies. Note that these ... You may have noticed headlines at the end of last ... Cox-2 inhibitor (Bextra) off the market. , ,This stronger-than-expected action ...
badgernet badgernet badgernet ,badgernet badgernet badgernet ,badgernet badgernet badgernet ,badgernet badgernet badgernet badgernet badgernet...
... voted late Tuesday night to amend a bill granting ... newly created human embryonic stem cells would be denied. ... firms that do any research involving the destruction of ... cells from them after August 9, 2001. It ...
Cached Biology Technology:Midwest large-cap life-science sector is solid in first quarter 2Bill would deny tax credits to firms creating stem-cell cultures 2
(Date:7/25/2014)... CORAL SPRINGS, Florida , July 25, 2014 /PRNewswire/ ... influential as more consumers are turning to digital technology ... NXT-ID, Inc. (OTCBB: NXTD), Google Inc. (NASDAQ: ... Visa Inc. (NYSE: V ), Apple Inc. ... FTNT) NXT-ID, Inc., (OTCQB: NXTD) a biometric ...
(Date:7/24/2014)... Scientists at The New York Stem Cell ... to creating a viable cell replacement therapy for ... , For the first time, NYSCF scientists generated ... samples of patients with primary progressive multiple sclerosis ... induce these stem cells into becoming oligodendrocytes, the ...
(Date:7/24/2014)... Angeles, where electric cars ply silent freeways, solar panels ... beneath the earth, from howling winds and from the ... that it is technically and economically feasible to convert ... renewable energy. Published in Energy , the plan ... energy supply in California that could create tens of ...
Breaking Biology News(10 mins):Consumer Needs for Identity Theft Security Grows with Popularity of Latest Smart Technology Products - Biometrically Secure Digital Wallet to Replace Credit Card Dependency 2Consumer Needs for Identity Theft Security Grows with Popularity of Latest Smart Technology Products - Biometrically Secure Digital Wallet to Replace Credit Card Dependency 3Consumer Needs for Identity Theft Security Grows with Popularity of Latest Smart Technology Products - Biometrically Secure Digital Wallet to Replace Credit Card Dependency 4Consumer Needs for Identity Theft Security Grows with Popularity of Latest Smart Technology Products - Biometrically Secure Digital Wallet to Replace Credit Card Dependency 5Consumer Needs for Identity Theft Security Grows with Popularity of Latest Smart Technology Products - Biometrically Secure Digital Wallet to Replace Credit Card Dependency 6NYSCF scientists 1 step closer to cell therapy for multiple sclerosis patients 2Stanford study shows how to power California with wind, water and sun 2Stanford study shows how to power California with wind, water and sun 3Stanford study shows how to power California with wind, water and sun 4
... -- Neither births nor deaths stop the flocking of organisms. ... of the University of Oregon. The notion, he says, has ... therapies. Picture any scenario in which self-propelled organisms -- ... even tiny plastic rods on a vibrating table -- move ...
... Nanoparticles have many useful applications, but also raise ... shows that plastic nanoparticles are transported through the aquatic ... full report is published Feb. 22 in the open ... to nanoparticles slowed their feeding behavior, and also affected ...
... at Buffalo engineers have developed a one-step, low-cost method ... from a single perspective, the polymer is rainbow-colored, reflecting ... filter for light, this material could form the basis ... color" of objects examined. An image of the material ...
Cached Biology News:New theory shows that neither birth nor death stops a flock 2New theory shows that neither birth nor death stops a flock 3A rainbow for the palm of your hand 2
... Plasma Immunodepletion Kit specifically removes 20 of ... or serum in preparation for further proteomics ... the plasma proteome whether you use one- ... or go straight to mass spectrometry. This ...
... a direct antibiotic-based selection ... Recombinant selection depends solely ... the need for costly ... and inexpensive process provides ...
... can perform many sophisticated DNA analysis and protein ... than just another sequence analysis product. Imagine having ... analyses to be performed each time you have ... sheets which specify exactly how your output will ...
... is the first fully automated proteomics workcell. ... operations with complete data tracking. It automates ... picking through final protein expression and measurement. ... delivering a plate to any of its ...
Biology Products: